[go: up one dir, main page]

Rahman et al., 2024 - Google Patents

Mitochondrial targeting improves the selectivity of singlet‐oxygen cleavable prodrugs in NMIBC treatment

Rahman et al., 2024

Document ID
7461723190231098150
Author
Rahman K
Bist G
Kumbham S
Foster B
Woo S
You Y
Publication year
Publication venue
Photochemistry and Photobiology

External Links

Snippet

Mitochondria play an essential role in cancer treatment by providing apoptotic signals. Hexyl aminolevulinate, an FDA‐approved diagnosis for non‐muscle invasive bladder cancer, induces the production of protoporphyrin IX (PpIX) preferentially by mitochondria in cancer …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
    • A61K47/48061—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being a heterocyclic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Similar Documents

Publication Publication Date Title
Gao et al. A dual‐functional photosensitizer for ultraefficient photodynamic therapy and synchronous anticancer efficacy monitoring
Zhang et al. Targeted delivery of a mannose‐conjugated BODIPY photosensitizer by nanomicelles for photodynamic breast cancer therapy
Shen et al. A near-infrared, wavelength-shiftable, turn-on fluorescent probe for the detection and imaging of cancer tumor cells
Dunkel et al. Targeted cancer therapy using compounds activated by light
He et al. Mitochondrion‐anchored photosensitizer with near infrared‐I aggregation‐induced emission for near infrared‐II two‐photon photodynamic therapy
Lai et al. Special reactive oxygen species generation by a highly photostable BODIPY-based photosensitizer for selective photodynamic therapy
Piskorz et al. Diazepinoporphyrazines containing peripheral styryl substituents and their promising nanomolar photodynamic activity against oral cancer cells in liposomal formulations
Wei et al. Glutathione-Exhausting Nanoprobes for NIR-II fluorescence imaging-guided surgery and boosting Radiation Therapy Efficacy via Ferroptosis in breast Cancer
Shi et al. An activity‐based photosensitizer to reverse hypoxia and oxidative resistance for tumor photodynamic eradication
Bhardwaj et al. Fluorophore‐Labeled Cyclooxygenase‐2 Inhibitors for the Imaging of Cyclooxygenase‐2 Overexpression in Cancer: Synthesis and Biological Studies
Rahman et al. Mitochondrial targeting improves the selectivity of singlet‐oxygen cleavable prodrugs in NMIBC treatment
Zhou et al. Synthesis and in vitro anticancer activity of zinc (II) phthalocyanines conjugated with coumarin derivatives for dual photodynamic and chemotherapy
Arslan et al. A leucine aminopeptidase activatable photosensitizer for cancer cell selective photodynamic therapy action
Koo et al. Harnessing GLUT1‐targeted pro‐oxidant ascorbate for synergistic phototherapeutics
Huang et al. A novel zinc phthalocyanine-indometacin photosensitizer with “three-in-one” cyclooxygenase-2-driven dual targeting and aggregation inhibition for high-efficient anticancer therapy
Chen et al. A photoactivatable theranostic probe for simultaneous oxidative stress-triggered multi-color cellular imaging and photodynamic therapy
Fraix et al. Light‐Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells
Dąbrowski et al. Tissue uptake study and photodynamic therapy of melanoma‐bearing mice with a nontoxic, effective chlorin
Vicente et al. Syntheses and preliminary biological studies of four meso-tetra [(nido-carboranylmethyl) phenyl] porphyrins
Li et al. Mitochondria-targeting BODIPY-loaded micelles as novel class of photosensitizer for photodynamic therapy
Li et al. Characterization of nanoparticles combining polyamine detection with photodynamic therapy
Digby et al. Photocaged DNA-binding photosensitizer enables photocontrol of nuclear entry for dual-targeted photodynamic therapy
Justiniano et al. The endogenous tryptophan‐derived photoproduct 6‐formylindolo [3, 2‐b] carbazole (FICZ) is a nanomolar photosensitizer that can be harnessed for the photodynamic elimination of skin cancer cells in vitro and in vivo
Herceg et al. Design, synthesis and in vitro evaluation of β-glucuronidase-sensitive prodrug of 5-aminolevulinic acid for photodiagnosis of breast cancer cells
Rahman et al. Singlet oxygen activatable prodrugs of paclitaxel, SN‐38, MMC and CA4: nonmitochondria‐targeted prodrugs